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Platinum(II) anticancer medications essentially react with DNA forming kinks in
the double helix of DNA and causing apoptosis. It has also been noted that these
anticancer medications react with methionine and cysteine in the body. With the new
discoveries of selenium containing amino acids including selenomethionine and
selenocysteine, new research is ongoing to see what types of products can be formed
from these amino acids. Our research reacts [Pt(Met-S,N)Cl2] 2+ with selenomethionine
to determine what types of products are produced. Monochelates including [Pt(SeMetSe,N)Cl2] 2+ have formed two isomers, as well as other products that insinuate both
selenomethionine and methionine binding with the platinum to form various [Pt(SeMetSe,N)(Met-S,N)] 2+ products. When initially reacting 6 mM [Pt(Met-S,N)Cl2] 2+ with 3
mM SeMet, the monochelates of both are produced without forming any free methionine
which would suggest that there is free platinum in our solution creating the SeMet
monochelate. When adding additional SeMet to the solution the same products are
formed that are created when reacting 6 mM [Pt(Met-S,N)Cl2] 2+ and 6 mM SeMet. The
1

H NMR spectrum for these products imply a product of [Pt(SeMet-Se,N)(Met-S,N)] 2+.

Also, reactions with [Pt(en)(ox)] 2+ and SeMet were conducted and produced various
products at two different pH’s. A [Pt(SeMet-Se,N)2] 2+ product was formed at lower pH
and produced free ethylenediamine, however at a higher pH only [Pt(en)(SeMet-Se,N)] 2+
was produced.
viii

I.

A.

INTRODUCTION

History
According to the National Cancer Institute, around 1,638,910 human beings

would be diagnosed with cancer, and 577,190 of them would die from cancer in the
United States in 2012.1 On January 1, 2009, there were approximately 12,553,337 men
and women alive that have had some form of cancer, which included people with cancer
at that time or that had been cured of cancer at a previous point in their life.1 Odds are
that most everyone in the U.S. population either knows someone directly or indirectly
that has been affected by cancer. Current anti-cancer medications have delivered results
to patients that help them cope with the symptoms or allow the patient to go into
remission. One field of anti-cancer medications that is being studied is platinum(II)
compounds; currently there are three platinum-containing FDA approved medications on
the market for patients. The first to ever be approved is Cisplatin, (cisdiamminedichloroplatinum(II)). Carboplatin, (cis-diamminecyclobutanedicarboxylatoplatinum(II)), is a second generation platinum-containing anticancer medication and was developed with fewer side effects than that of cisplatin.
Oxaliplatin, ((1R,2R-diamminocyclohexane) oxalatoplatinum(II)) is a third generation
medication and works for patients that are resistant to cisplatin and carboplatin.
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Structures of Cisplatin, Carboplatin and Oxaliplatin 3 contains the FDA approved
platinum structures of Cisplatin, (cis-diamminedichloroplatinum(II)), Carboplatin, (cisdiammine-cyclobutanedicarboxylatoplatinum(II)) and Oxaliplatin, ((1R,2Rdiamminocyclohexane) oxalatoplatinum(II)).
The cisplatin compound was actually first synthesized in 1845 by Michael
Peyrone.3 Its anti-cancer activity wasn’t discovered until the 1960’s, and clinical trials
intravenously in humans were completed by mid-1972.4 The clinical trials showed
major advantages in testicular cancers, but also had produced renal toxicity in patients.4
There were other toxicities that developed in other patients including ototoxicity,
hematological toxicity, neuropathy and seizures. Ultimately, the studies led to the 1978
FDA approval of cisplatin for the treatment of testicular and ovarian cancer. The drug
also plays an important role in the treatment of other cancers, including, head and neck
cancers, melanoma, bladder cancer and cervical cancers and many more other types of
cancers.5
During 1967 at Michigan State University, Dr. Barnett Rosenberg published an
article in the Journal of Bacteriology stating that the platinum salt, ammonium
hexachloroplatinate(II), was responsible for inhibiting cell division.2 A study was done
in Dr. Rosenberg’s lab trying to see how an electric field would affect the growth process
of bacteria, specifically E. coli.2 It was then found that a platinum salt that was being
produced in the electric field inhibited cell division but had no effects on cell growth.2
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The platinum salt was identified to be [PtCl6]2-; the media containing the platinum salt
and free ammonia that had also been exposed to ultraviolet radiation actually produces
three different ligand platinum compounds, all with different effects on the bacteria.2
Ammonium hexachloroplatinate(II) was one of the compounds that acted as a
disinfectant and killed the bacteria.2 The second compound was [PtCl5NH3]- and seemed
to have no effect on the bacteria.2 The last platinum compound formed was
[PtCl4(NH3)2] and was the most stable species; this compound seemed to have an
inhibition on cell division, but did not affect the cell growth.2 It was then decided that
platinum salts should be studied to determine its biological effects.
When it became obvious to Dr. Rosenberg’s lab that platinum metal has more
than one oxidation state and there were different configurations being produced, cis and
trans, four compounds were studied in mammalian cells. Success was achieved with the
[PtCl4(NH3)2] in the +2 oxidation state and with a cis configuration. The thought was
that the platinum compounds would inhibit cell growth in tumor cells but have no effect
on the host animal. There were four different platinum compounds that were tested in
mice, shown below in Figure 1.2.

3

Figure 1.2)

Structures of Platinum Compounds: (1) cis-Pt(IV)(NH3)2Cl4; (2) cis-Pt(II)(NH3)2Cl2;
(3) Pt(II)(NH2CH2CH2NH2)Cl2; and (4) Pt(IV)(NH2CH2CH2NH2)Cl4.
The compounds that showed the most successful anti-cancer activity were
compounds 2 and 4.5 They were tested against Sarcoma-180 tumors in mice, and the
tumors actually had shrunk in size due to the platinum compounds.5 The mice survived
the treatment, and after 6 months of being treated they still showed no signs of cancer.5
Based on these results, this was when compound two entered clinical trials in humans and
showed promising results.
There are a few different mechanisms proposed for the anti-cancer activity of
cisplatin, but the one that is most widely accepted proposes the drug reacts with DNA and
causes apoptosis.5 When cisplatin enters the blood stream via intravenous exposure; the
chloride ligands remain attached due to the high concentration of chloride in blood
plasma.5 Once inside the cell the chloride ligands are replaced with water due to the
concentration difference; the chloride concentration inside the cell is only 4 mM as
opposed to 10 mM in blood plasma.5 Replacement of the chlorides creates a positively
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charged compound that is now in its active form, and this form cannot readily leave the
cell. From here the platinum compound enters the cell nucleus and reacts with DNA;
usually two adjacent guanine residues on the double helix.5 Cisplatin can also bind to
adjacent adenine-guanine residues. Binding to adjacent residues causes the double helix
to form a kink and become bent, which allows for the DNA binding protein to attach and
either repair the DNA or initiate cell death.5 When the platinum compound attaches to
DNA via guanine residues, specifically at the N7 position of the guanine residue, it
typically forms a 1, 2 G-G intra-strand crosslink.5 Other possible products are formed
including, 1, 2 A-G, and 1, 3 G-G intra-strand crosslinks, 1,2 and 1,3 G-G inter-strand
crosslinks, and DNA-protein crosslinks.6 Below is a depiction showing the mechanism
of binding with cisplatin and DNA.
Figure 1.3)

Mechanism of Action for Cisplatin: cisplatin reacting with the double helix and
forming the various crosslinks causing apoptosis.3
5

B.

Chemistry of Platinum Compounds
Around the early 1900’s cisplatin’s geometry became the debate and topic for Alfred

Werner’s theory of coordination chemistry.5 Werner’s theory showed two isomers that
were formed, a cis and a trans, hence the name cisplatin and transplatin.5 He also
suggested the square planar configuration correctly, and won the Nobel Prize for
Chemistry in 1913.5
Figure 1.4)
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Structure of Cisplatin and Transplatin.
Years later, scientists had studied how the structure contributed to the compounds
anticancer activity. Cleare and Hoeschele, developed the “structure-activity
relationships,” and suggested what should be structurally required of a compound, as
listed below:5
•

The compound should contain two amine groups in a cis position, because the
trans geometry is inactive.

•

It should contain two leaving groups, also with a cis geometry relative to each
other.

•

The ability of the leaving groups to be lost, contribute to the toxicity and
activity of the compound. It’s suggested that the leaving groups be easily
removed.

•

The compound should also not have an overall charge.
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•

The greater the activity of the compound, the fewer the alkyl substituents on
the amine ligands, and each ligand should contain at least one proton.

The general structure for these compounds should have a similar configuration to
the structure in Figure 1.5:
Figure 1.5)
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General Structure for Platinum(II) Compounds: X=leaving groups (two chloro
groups or a bidentate malonate), and ligand R=H or an alkyl substituent.5

Any new platinum-containing anti-cancer drug to be considered for clinical trials
must possess one of the following characteristics: to be delivered as an oral medication,
generate reduced toxic side effects, and/or have activity against cancers with intrinsic or
acquired resistance to cisplatin treatment.5 Any type of platinum compound that has
deviated from the general structure will change the reactivity of the compound and how it
reacts with DNA. For example steric effects such as bulky amine ligands slow the
reaction with DNA.7 A bulky amine ligand on a square planar platinum complex
reduces the rate of the reaction with DNA and also slows down the binding to thiol
containing proteins, which potentially reduces side effects and toxicity.7
Since the drug must travel many places in the body before it ultimately reaches
cellular DNA, there are many other prospective biomolecules with which the compound
has the ability to react. Platinum compounds have a high affinity for sulfur-containing
7

compounds, which is explained by the HSAB (Hard Soft/Acid Base) theory. The HSAB
theory states that “soft acids” tend to favor “soft base,” and likewise with hard acids and

bases; therefore, the “soft” sulfur atom will donate a ligand to the “soft” platinum
compound. Potential targets that contain the sulfur atom are proteins that contain the

amino acids methionine (Met) and cysteine (Cys). In theory, these reactions of platinum
and the amino acids would be thermodynamically and kinetically favored, because of
basic coordination chemistry knowledge.

Figure 1.6)

Structure of Cysteine and Methionine
platinum(II)
(II) molecules react with certain
The HSAB theory helps explain why platinum

amino acids and proteins. The theory was developed in the 1960’s by Ralph Pearson, and
also known as the donor-acceptor theory.9 Pearson categorizes acids and bases upon their
ability to polarize, their size and valence electrons. Lewis acids and bases are easily
polarizable, larger in size, and typically have a lower charge (+1, +2).10 All Lewis soft

acids are electron acceptors, and soft bases are electron donors.10 A few examples of
soft acids include Cu+, Au+, Ag+, Hg2+, and Pb2+; and for soft bases this includes, S2-, I-,
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Br-, and RSe-.10 Hard acids and bases are typically not polarizable, smaller in size and
have a higher charge (≥+3).10 Examples of hard acids include the s, and f blocks of the
periodic table, Mg2+, Fe3+ and Al3+.10 Some examples of hard bases include specific
compounds that include ox ygen and fluorine, such as O2-, F-, OH2, CO32-, and PO43-.10
Therefore, when reacting a soft acid, it will prefer a soft base; likewise hard acids are
preferential to hard bases.

The donor-acceptor theory has been useful in helping researchers understand why
metal ions in the body typically bind with some types of sulfur containing proteins.
Cisplatin and other platinum(II) containing anti-cancer drugs react with proteins
containing methionine and/or cysteine. The platinum anti-cancer drug is a soft acid, and
the sulfur biomolecules are soft bases. T
The
he sulfur will donate its electrons to the
platinum, which is the electron acceptor. There are other biomolecules that contain

selenium in place of sulfur, selenomethionine (SeMet) and selenocysteine (SeCys), and
donate electrons to platinum anti-cancer drugs.
Figure 1.7)

Structure of Selenocysteine and Selenomethionine
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C.

Reactions of Platinum Anti-Cancer Agents with Biomolecules
After the platinum(II) drug is given intravenously to the patient, the drug enters the

blood stream where it enters the cell, passes into the nucleus of the cell and reacts with
DNA. Before the medication enters the cell, there are many proteins available to react
with the drug, and the reaction with DNA is thought to lead to cytotoxicity. A question
researchers have been debating is why does platinum react with sulfur residues, but
ultimately ends up reacting with DNA. One thought to the question is that the reaction of
these platinum drugs with the amino acids cause toxicity and resistance.7 However, it
should be noted that Pt-S bonding also has positive effects in the body; examples include
preventing side effects, as well as using the Pt-S bond as optimal transport for the anticancer medication throughout the body.7 Platinum drugs can react with thiol residues of
cysteine-containing proteins, or the thioether residues of methionine-containing
complexes.8
Thioether residues are responsible for serving as a drug reservoir for platination at
DNA inside the cell. This is due to the concentration difference of the residues inside the
cell which are much higher than outside the cell.8 As a drug reservoir this gives two new
possible reaction pathways for DNA platination; either the instantaneous release of the
platinum from sulfur then the reaction with DNA occurs, or the guanine N-7 group on
DNA directly displaces the platinum from the sulfur.7 Thioether reactions serve as
intermediates and are kinetically favored.8 However, the thioether bond can be broken
by a thiol residue, the resulting bond is thermodynamically stable. Yet the bond is not
easily broken, and contributes to toxicity and resistance of the anticancer medication.8
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When the platinum binds to thiol containing groups, the Pt-S (thiol) bond contributes
to the occurrence of toxicities with platinum(II) complexes as anticancer agents.8
However, the Pt-S bond can be broken with the use of “rescue agents”, which are strong
nucleophiles also containing sulfur.8

“Rescue agents” or “protecting agents” are sulfur

containing compounds, administered with the Pt(II) anticancer medication. A few of
these rescue agents are sodium thiosulfate (STS), sodium diethyldithiocarbamate
(Naddtc), thiourea, glutathione (GSH), cysteine (Cys), methionine (Met), Nacetylcysteine, biotin and sulfathiazole.7 These compounds either prevent or terminate
the Pt-S adducts in proteins and do not lower the anticancer activity of the Pt(II)
complex.7 More research has been ongoing to determine the effects of these rescue
agents and their potential uses. Positive uses of these rescue agents include preventing
side effects as well as optimal transport.7 For example, it was known that GSH is
present in the cell has many functions, including detoxification of chemotherapeutic
agents. A clinical study with glutathione and cisplatin reported significantly reduced
toxicity in ovarian cancer cases with cisplatin as treatment.8
Other types of bonds can be formed with platinum(II) anticancer compounds, such as
selenium containing amino acids. Glutathione peroxidase and thioredoxin reductase
(TrxR) are two enzymes that contain selenocysteine, and have been shown to react with
platinum anticancer medications.11 Thioredoxin reductase contains a selenocysteine
residue in its active site which is an easy target for platinum anticancer medications.13
This enzyme has been shown to be inhibited due to reaction of platinum with
selenocysteine; the uninhibited enzyme plays important roles in maintaining redox
systems in the body.13 When the enzyme is inhibited, an increase of oxidized thioredoxin
11

(Trx) occurs, creating cellular conditions for stimulation of apoptosis.13 Selenocysteine
is deliberately added to proteins, as opposed to selenomethionine which is arbitrarily
inserted into proteins in place of methionine.11 Selenocysteine has a low pKa value and
is a strong nucleophile, which makes it difficult for the amino acid to exist freely in cells,
but is highly reactive when incorporated into proteins.14 Selenium containing compounds
have been studied for their antioxidant effects as protecting agents for toxicity and
resistance.11 Selenomethionine and S-methylselenocysteine showed increased survival
rates in mice when given a toxic dose of cisplatin and oxaliplatin.11
Disulfide bonds of oxidized glutathione (GSSG) have been studied for their
participation in the redox systems in the body and are known to form during protein
folding.16 Cysteine has the ability to partake in acid/base chemistry to form the disulfide
bonds, either as a catalytic redox component or to convey structural stability.16
Selenoglutathione (GSeSeG) was found to be more stable than GSSG and the
selenocysteine residues were capable of oxidizing cysteine residues in unfolded proteins,
which helps regain protein conformational stability upon folding.16
Previous studies have shown that natural diselenide bonds have been created and in
comparison to the disulfide bonds, diselenide bonds have a low redox potential.15 A
similar study showed that the diselenide bond in selenocystine was studied for its
reactivity with platinum anticancer drugs. The results concluded that the diselenide bond
could be split via the platinum structures, however, this meant that somehow redox
reactions and/or reducing agents were used to complete this.14 One structure used to
determine the ability to cleave the diselenide bond was [Pt(Met)Cl2] 2+.14 Results
indicated that [GS-Sec]- and [GSSG]- were formed indicating that platinum drugs could
12

potentially interfere with the electron transfer process from reduced glutathione to
glutathione peroxidase through the altering of the selenocystine residue therefore
reducing the antioxidant ability of glutathione peroxidase.14 These studies are important
to determine more information regarding these new selenium containing amino acids and
their antioxidant effects in regards to platinum anticancer medications.
Other studies have looked at how bulky amine ligands react with selenium containing
amino acids, as well as competition studies of sulfur vs. selenium with the bulky platinum
complexes. Our investigation of cisplatin analogs with SeMet and Met showed the
displacement of amine ligands due to the trans effect of selenium and sulfur ligation.11
In the same study when bidentate or tridentate ligands were used, the displacement of
amine ligands was less prevalent.11 One study showed that with the use of an
ethylenediamine (en) ligand on a platinum complex, it reacts with SeMet and produces a
bis-product of two selenomethionine residues joining the Pt(en) species forming
[Pt(en)(SeMet-Se)2] 2+.11 Chelation eventually occurs and displaces the en ligand to form
a bis-chelate product, ([Pt(SeMet-Se,N)2] 2+), and the remaining nitrogen on SeMet
residues coordinate to platinum forming a six-membered ring.11
The research that is presented in this thesis will report the effects of using
different leaving group ligands on bulky platinum(II) complexes and their reaction with
selenomethionine and selenocysteine variants. Particular amino acids that will be used
are L-Methionine, Seleno-L-Methionine, Seleno-L-Cystine, and Se(Methyl)selenocysteine. Our research will consist of the following platinum compounds:
ethylenediamine platinum(II) (oxalate and dinitrate groups) ([Pt(en)(ox)] 2+ or
[Pt(en)(NO3)2]2+). These studies will also lead us to react the previous made [Pt(Met13

S,N)Cl2] 2+ with selenomethionine to determine its reactivity. We will use NMR
spectroscopy, LC/MS, and HPLC to characterize our results. An attempt to react the
platinum compounds with the selenium-containing amino acids will be made at different
pH ranges as well as with different stoichiometric variations.
II.

EXPERIMENTAL

A Materials Used
The following items were purchased from Sigma Aldrich: Sodium Chloride (NaCl),
Potassium Tetrachloroplatinate(II) (K2PtCl4), Silver Nitrate (AgNO3),
Dichloro(ethylenediamine)platinum(II) ((H2NCH2CH2NH2)PtCl2), Deuterium Oxide
(D2O), and Se-(Methyl)selenocysteine Hydrochloride. From Acros the following were
purchased: Anhydrous Oxalic Acid, L-Methionine, L-Selenocystine, and LSelenomethionine.
B NMR
A JEOL Eclipse 500MHz Nuclear Magnetic Resonance was used to characterize
products using deuterium oxide as a solvent. When adjusting the pH of the different
solutions made, 1.0% deuterated nitric acid and 1.0% sodium deuteroxide were used.
Typically only a proton (1H) NMR scan was utilized; however, occasionally other scans
were used including a HMQC (Heteronuclear Multiple Quantum Coherence), and a
COSY (COrrelation SpectroscopY).
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C LC/MS
An Agilent 1100 HPLC coupled with a MSD (SL) ion-trap electrospray ionization
spectrometer system was used to acquire the mass spectrometry data for these
experiments. The sample was introduced into the mass analyzer by the mobile phase
solution of Methanol:Water (80:20) and injected at a flow rate of 200 µL min-1. The
voltage used for the electrospray needles was 3.5 kV, the capillary temperature was
350 ˚C and recorded in negative ion mode. The isotopic distribution pattern for each
complex was simulated with the Isopro 3.0 program.
D Synthesis of Platinum(II) Methionine Dichloride [Pt(Met)Cl2]2+
[Pt(Met)Cl2]2+ was made according to the method described by Norman et al.12 A
solution containing potassium tetrachloroplatinate(II) (10.5 mg, 25.3 µmol), sodium
chloride (4.5 mg, 77 µmol), and L-Methionine (3.5 mg, 23.3 µmol) were dissolved in 0.6
mL of deuterium oxide. The solution was mixed in an amber vial and heated in a water
bath at 353 K for 10 minutes. This produced a clear yellow solution with a pH of 1.6. A
6 mM solution of [Pt(Met)Cl2] 2+ was made as described by Liu et al.13 The solution was
made by obtaining 142 µL of the [Pt(Met)Cl2] 2+ and diluted with 858 µL of deuterium
oxide.
E Synthesis of Platinum(II) Selenomethionine Dichloride [Pt(SeMet)Cl2] 2+
Two solutions of [Pt(SeMet)Cl2] 2+ were similarly made to that of [Pt(Met)Cl2]2+.
The first solution was made using an amber vial and 10.5 mg of potassium
tetrachloroplatinate, 4.9 mg of selenomethionine and 4.5 mg of sodium chloride in 0.6
mL of deuterium oxide. The solution was heated for ten minutes in a water bath at 353
15

K, and produced a yellow solution with a pH of 1.5. To yield a 6 mM solution, 142 µL of
the original sample was mixed with 858 µL of deuterium oxide. The second solution was
made the exact same way except there was no sodium chloride added, and the pH initially
was 1.1, adjusting the pH to 9-10, using 1% sodium deuteroxide, the reactants finally
dissolved in solution. Again, 142 µL [Pt(Met)Cl2] 2+ was mixed with 858 µL of
deuterium oxide and adjusted the pH to 7.0 to obtain a final 6 mM solution.
F Preparation of Selenomethionine Solutions
For a 6 mM solution of selenomethionine, 2.4 mg of the amino acid was dissolved in
1.0 mL of deuterium oxide and pH was adjusted to 8. Typically for a 1:2 ratio of
platinum:SeMet, 500 µL of each solution was mixed together. For a 3 mM solution of
selenomethionine, 0.6 g of the amino acid was dissolved in 1.0 mL of deuterium oxide.
Usually the pH of these solutions would eventually be adjusted either to around 3-4 or 78, using 1.0% sodium deuteroxide and/or 1.0% deuterated nitric acid.
G Preparation of Methionine, Selenomethionine and Platinum Compound
This solution was made as two separate mixtures and then combining the mixtures
together. For the first vial, 2.35 mg of selenomethionine was added to 1.8 mg of
methionine in 1.0 mL of D2O and stirred for around 2 hours. The second solution was
made with 10.5 mg (25.3 µmol) of potassium tetrachloroplatinate(II), 4.5 mg of sodium
chloride in 1.0 mL of D2O and also stirred for about 2 hours. Both mixtures were then
combined into one vial having an initial pH of 1.8, then adjusted to 6.5. After the pH was
adjusted, the solution was left in an 80˚C heat bath overnight. All solutions were mixed
at an equimolar ratio of 25.3 µmol.
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H Preparation of [Pt(en)ox]2+
This solution was made with 50 mg of silver oxalate, 50 mg of
dichloro(ethylenediamine)platinum(II) in 30 mL of water and stirred for a few hours to
ensure the reaction complete. Next the solution was syringe filtered and placed on a
rotovap and the ending product weight was 18.9 mg.
I

Reactions with [Pt(en)ox]2+ with Selenomethionine

For a solution containing excess selenomethionine by weight, 2.0 mg of [Pt(en)ox] 2+
was mixed in 1.0 mL of D2O, and in another vial 1.0 mg of selenomethionine was
dissolved in 1.0 mL of D2O. Both solutions were allowed to stir separately and then a
500 µL aliquot of [Pt(en)ox] 2+ was added to the selenomethionine solution and resulted
in a pH of 4.6. Another sample with similar quantities of reagents was prepared except
with this solution, the pH of both samples were raised to 7.0 before mixing and then after
mixing samples together the pH was adjusted to 6.9.
A sample containing excess platinum was mixed using 4.0 mg of [Pt(en)ox] 2+ in 1.0
mL of D2O in one vial, and in a separate vial 1.0 mg of SeMet was mixed in 1.0 mL of
D2O. Both solutions were allowed to stir separately overnight and then the next day both
solutions were mixed together and allowed to stir for around 3 hours and resulted in a pH
of 5.0.
III.

RESULTS

Initially this project began by replicating Liu et al. paper, by trying to reproduce the
selenocystine cleavage that they had accomplished.14 We were unable to do so, which
lead us to reactions with selenomethionine. Having previously worked with
selenomethionine, products are simpler to assign using 1H NMR. Using various
17

platinum(II) compounds with ammine ligands, such as [Pt(en)(D2O)2]2+
(en=ethylenediamine) and [Pt(Me4en)(D2O)2] 2+, (Me4en= N,N,N’,N’tetramethylethylenediamine
tetramethylethylenediamine)) and having reacted with SeMet, typically the less bulky

ammine ligand will displace from platinum allowing the formation of bischelate
products.11 For example, the ethylenediamine ligand does displace from platinum
forming various products, while the Me4en ligand does not become displaced and allows
for only the formation of monochelate products.11 With these results and the results of

Liu et al. paper, using selenomethionine and [Pt(Met)Cl2] 2+ were reacted at various
ratios forming several products.
A Reactions with [Pt(Met)Cl2] and Selenomethionine
To begin, using a method previously described by Norman et al., a 1:1 mixture of

K2PtCl4 was mixed with methionine to form [Pt(Met-S,N)Cl2]. To confirm our results
LC/MS was used and a mass of 413 was observed in negative ion mode, which is

comparable to that obtained via Liu et al. paper. The following 1H NMR spectrum shows
the two major isomers formed
formed,, following the two structures for both isomers:

Figure 3.1)

Isomer A
Isomer B

γ hydrogens
α hydrogens

1

H NMR Spectrum of [Pt(Met-S,N)Cl2] 2+
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β hydrogens

Figure 3.2)
COO H C
3

S
Pt
Cl

CO O H C
3

N H2

S
Pt

Cl

Cl

N H2
Cl

Structures of [Pt(Met-S,N)Cl2] 2+The left structure is isomer
A (R configuration at S, envelope ring conformation) and
the right structure is isomer B (S configuration at S,

Figure 3.3)
Se-CH3

Hγ

Hα

1

Hβ

H NMR Spectrum of Selenomethionine

To determine the possible products that could be potentially produced, solutions
containing plausible products were made. This included making [Pt(SeMet)Cl2] 2+

products, adapting Norman et al. method of making a 1:1 solution of [Pt(Met)Cl2] 2+.
Mixing 10.5 mg of potassium tetrachloroplatinate(II), 4.9 mg of selenomethionine and
4.5 mg of sodium chloride in 0.6 mL of deuterium oxide in an amber vial and heating it

in a heat bath at 80˚C for ten minutes gave a yellow solution with a pH of 1.5. Using 142
µL
L of said sample and mixing it with 848 µL of deuterium oxidee produced the following

spectrum:
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Figure 3.4)

Se-CH3 peaks

1

H NMR Spectrum of [Pt(SeMet-Se,N)Cl2] 2+

The monochelate products have two isomers possible, depending on which way
the methyl group is pointing. This proton NMR spectrum clearly depicts two major
isomers forming in solution. The figure below shows two possible structures for the

SeMet monochelates:
Figure 3.5)

CO O -

COO H C
3

Se N H
2
Pt
Cl
Cl

H C
3

Se N H
2
Pt
Cl
Cl

Structures of [Pt(SeMet-Se,N)Cl2] 2+

To further characterize products, an attempt to make the selenomethionine

bischelate was made similarly to Norman et aal.
l. Using 27.0 mg of potassium
tetrachloroplatinate, 26.1 mg of selenomethionine (133 µM),
M), and 6.0 mg of sodium
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chloride was mixed with 0.6 mL of D2O in a heat bath at 343 K for two minutes and

produced a clear yellow solution with a pH of 1.6. The pH was adjusted to 6.5 and the
solution turned colorless, the following spectrum shows the products produced:

Figure 3.6)

Se-CH3 peaks of the three
different cis isomers formed
Additional
β-hydrogens
γ-hydrogens of the
three isomers

α-hydrogens of the
three isomers

1

β-hydrogens of the
three isomers

H NMR Spectrum of [Pt(SeMet-Se,N)2] 2+

Figure 3.7)

cis-[Pt(SeMet-Se,N)2-RR

cis-[Pt(SeMet-Se,N)2-SS
cis-[Pt(SeMet-Se,N)2-R
cis-[Pt(SeMet-Se,N)2-S

Expanded 1H NMR Spectrum of [Pt(SeMet-Se,N)2] 2+

21

When assigning peaks to each of the isomers, we compared our spectra to those
assigned previously.11 It has been previously noted that SeMet chelates have a stronger
π-accepting ability when compared to sulfur-containing chelates, and that a cis geometry
is favored over a trans geometry.11 Typically, trans S-containing chelates have much
broader signals in 1H NMR than Se-containing chelates. Also, using LC/MS a mass of
585 was recorded when using negative ion mode, which also corresponds to the
bischelate product. Other masses recorded was 621 which corresponds to [Pt(SeMetSe,N)(SeMet-Se,Cl)], and also a little less abundant was a mass of 460 which corresponds
to the [Pt(SeMet-Se,N)(Cl2)], the monochelate.
In the original paper by Liu et al., to obtain the various products a 6 mM,
[Pt(Met)Cl2] 2+ was reacted with 3 mM selenocystine. Our project used similar ratios, 6
mM [Pt(Met)Cl2] 2+ with 3 mM SeMet. First, a solution of the [Pt(Met)Cl2] 2+ was made
and a separate solution of the SeMet was mixed, taking a 500 µL aliquot of both
solutions, they were mixed and left overnight in a heat bath of around 70˚C. The initial
pH of the solution after mixing was 2.4, after leaving it in the heat bath overnight, not
much had changed of the proton NMR peaks, so the pH was raised to 6.3 and put back
into the heat bath for another night. The reaction produced the following 1H NMR
spectrum:
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[Pt(Met)Cl2] peaks

Figure 3.8)

[Pt(SeMet)Cl2] peaks

1

H NMR Spectrum of [Pt(Met-S,N)Cl2] 2+ with SeMet

When comparing [Pt(Met-S,N)Cl2] 2+ S-CH3 peaks to Se-CH3 [Pt(SeMetSe,N)Cl2] 2+ peaks, selenium is typically up
upfield
field of sulfur peaks, and comparing to that of
the Norman et al. paper we determined the two small peaks around 2.38 ppm were the
selenomethionine monochelates. We expected the selenomethionine chelates to form and
the methionine monochelate would be knocked off and free methionine would be visible;
however, from our spectrum we do not see any free methionine. This leads us to believe

that there may be free potassium tetrachloroplatinate(II) in our [Pt(Met)Cl2] 2+ solution,
which would not show up in a proton NMR spectrum. Next, 0.3 mg of selenomethionine
was added to the solution to see if the monochelate peaks would become more prominent.

Allowing around 2 hours for the reaction to finish there was still free selenomethionine in
solution. The reaction was heated to 80˚C in a water bath overnight, and the pH had

dropped the next day to around 2.8
2.8.. It was noted that all of the selenomethionine had
been used up and produced the following spectrum:
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Figure 3.9)

1

H NMR Spectrum after additional SeMet added

The pH of the solution had dropped to 2.8, and the previous peaks that were
visible had now turned into two different sets of three peaks. The first black circle
around the first three peaks refers to one product, while the second black circle around

the other set of three peaks refers to another product. Typically, when these types of
peaks are formed, this suggests the formation of both Met and SeMet attaching to the

platinum to form bischelates as [Pt(SeMet-Se,N)(Met-S,N)]. After performing LC/MS on
the sample a mass of 574 (M-1) was observed which corresponds to either SeMet or Met
chelating while the other is only a monoadduct and a Cl- attached to the platinum, thus
forming something like [Pt(SeMet-Se,N)(Met-S)Cl] or [Pt(Met-S,N)(SeMet-Se)Cl]. The
following figure depicts possible structures produced in the reaction:
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Figure 3.10)

Structures of SeMet/Met Monoadduct/Monochelate

Subsequently, a reaction consisting of 6 mM [Pt(Met)Cl2] 2+ and 6 mM SeMet

was mixed and the pH was adjusted up to 6.5 and produced the following spectrum:
Figure 3.11)

Se-CH3

S--CH3

1

H NMR Spectrum of 1:1 [Pt(Met-S,N)Cl2] 2+ & SeMet

The reaction was placed in an 80˚C water bath overnight and the pH had dropped
to 6.1, spectrum obtained after two weeks is shown in the following figure:
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Figure 3.12)

Se-CH3

S-CH3

1

H NMR Spectrum of 1:1 [Pt(Met-S,N)Cl2] 2+ & SeMet after 2 weeks

Figure 3.13)

Expanded 1H NMR Spectrum of [Pt(Met)Cl2] 2+ & SeMet

After 2 weeks of the reaction, it still seems there is a little free methionine
available, which would insinuate that tthe
he selenomethionine is displacing the methionine,

allowing selenomethionine to bind. Expanding the spectrum, two sets of three peaks are
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very similar to each other and also comparable to what the previous reaction turns into
after extra selenomethionine is added to the reaction. This again implies that both
selenomethionine and methionine are binding to the platinum to form [Pt(SeMet-

Se,N)(Met-S,N)]. After running LC/MS a mass of 538 (M-1) is observed which
corresponds to both methionine and selenomethionine being chelated to the platinum.
The following figure depicts the structure of the plausible products formed:

Figure 3.14)

Strucutre of [Pt(SeMet-Se,N)(Met-S,N)]2+
The succeeding result was formed by mixing SeMet and Met in one vial

while K2PtCl4 and NaCl were mixed in a separate vial, after said solutions were dissolved
both vials were mixed all together. Potassium tetrachloroplatinate and sodium chloride
were mixed as one 12 mM solution, a separate solution of 12 mM selenomethionine and

12 mM methionine were mixed. The two solutions were mixed together resulting in a pH
of 1.8. The pH of the mixture was adjusted to 6.5 and put in an 80˚C heat bath overnight.
The next day the pH had dropped to 4.0 and produced the following 1H NMR spectra:
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Figure 3.15)

1

H NMR Spectrum of Competition Reaction with SeMet & Met

Figure 3.16)
[Pt(Met)Cl2]
[Pt(SeMet)Cl2]

Expanded 1H NMR Spectrum of Competition Reaction

The previous spectra show the monochelates formed by SeMet and Met giving

[Pt(SeMet)Cl2] 2+ and [Pt(Met)Cl2] 2+. To ensure that the reaction was complete, the
mixture was put back into the 80˚C heat bath again overnight, and the pH had not
changed significantly. The reaction observed for the next week and the final spectrum of
the reaction is shown in the following figure:
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Figure 3.17)
S-CH3
monochelate
peaks

Se-CH3
monochelate
peaks

New peaks

1

H NMR Spectrum of Competition Reaction after 1 week

B Reactions with [Pt(en)ox] 2+ and Selenomethionine
Oxaliplatin was a third generation platinum(II) anticancer medication approved that
contains a DACH ligand (DACH=1,2-diaminocyclohexane) giving the compound a
higher stability which leads to different reaction pathways than cisplatin and

carboplatin.17 According to Küng et al., the S,N chelate of methionine is produced with
the DACH ligand still coordinated to the platinum, when the oxalate is the leaving group.
When reacting 5’-GMP (GMP=guanosine monophosphate), with methionine and
oxaliplatin, not only is the mon
monochelate
ochelate of methionine produced, but a species containing

two monoadducts of GMP-N7 are also produced, but Met and GMP do not displace one
another, which insinuates a competitive reaction for the platinum between the two.
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An oxaliplatin analog containing an ethylenediamine ligand and an oxalate leaving
group was reacted in our research with selenomethionine. These reactions took place at

pH 4.0 and 7.0 with excess SeMet or excess platinum, and formed various products.
The first experiment began with excess platinum in solution relative to
selenomethionine at a pH of around 4.0. This experiment produced the following 1H

NMR spectrum:
Figure 3.18)

[Pt(en)(SeMet-Se)ox]
)ox]

Impurity
[Pt(en)(SeMet-Se,N)]

1

H NMR Spectrum of [Pt(en)(ox)]2+ & SeMet at pH 4.0

Initially we see peaks corresponding to the monoadduct of selenomethionine and the
oxalate ligand, as well as the Se,N monochelate with the en ligand still attached as well.
There is also an impurity around 2.2 ppm from the deuterium oxide used. Five days later

another spectrum was produced
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Figure 3.19)

Free ethylenediamine ligand

1

H NMR Spectrum of [Pt(en)(ox)]2+ & SeMet after 5

After five days the monoadducts of SeMet have now turned into the monochelate

forming [Pt(en)(SeMet-Se,N)] 2+, as well as the remaining impurities. We can also note
that around 3.3 ppm, a small peak has begun showing which corresponds to the free
ethylenediamine ligand. This reaction had initially begun at a pH of 5.0 and after 5 days
the pH had dropped to 3.9
3.9,, due in part to the deprotonation of the amine nitrogen upon
coordination to the platinum.
The next reaction consisted of excess SeM
SeMet
et and had an initial pH of 4.6 and
produced the following spectra after four hours of the rreaction
eaction being mixed:
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Figure 3.20)
Free SeMet

[Pt(SeMet-Se,N)2]
[Pt(en)(SeMet-Se,N
Se,N)]

Free ethylenediamine ligand

1

H NMR Spectrum of [Pt(en)(ox)]2+ with excess SeMet at pH 4.0

At pH 4.0 with excess selenomethionine
selenomethionine,, it is obvious that there is more free
ethylenediamine produced initially here tha
than
n with excess platinum at the same pH. We
also can see a SeMet bischelate having been produced here as well. Another spectrum
was produced after approximately 20 hours of the initial reaction been mixed shown in

the following figure:
Figure 3.21)
Free SeMet
[Pt(en)(SeMet--Se,N)]
[Pt(SeMet-Se,N)2]
Free ethylenediamine

1

H NMR Spectrum of [Pt(en)(ox)]2+ & excess SeMet at
pH 4.0 after 20 hours
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In the above NMR spectrum we see the peak for the free ethylenediamine has
grown and there is still free selenomethionine. The SeMet monochelate is still being
produced as well as the SeMet bischelate. We can attribute the additional free

ethylenediamine to the pH difference when chelation occurs. When SeMet is chelating it
loses a hydrogen atom causing the pH to drop.
The next experiment consisted of the same conditions as the prior experiment
except the pH was adjusted to 7.0. For this reaction 2.0 mg of [Pt(en)ox] 2+ was mixed in

1.0 mL of D2O and the pH was adjusted to 7.0, while in a separate vial 1.0 mg of SeMet
was mixed in 1.0 mL of D2O and the pH was also adjusted to 7.0. Both solutions were
allowed to stir for 2 hours separately and then a 500 µL
L aliquot of the platinum solution
was mixed with the entire SeMet solution. Again the solution was allowed to stir for a

few hours and the pH was again adjusted to 7.0 and produced the following NMR
spectrum:
Figure 3.22)

Free SeMet

[Pt(en)(SeMet-Se,N)]

1

H NMR Spectrum of [Pt(en)(ox)]2+ & excess SeMet at pH 7.0

At a higher pH there are quite a few differences in the spectrum when compared
to that at a lower pH. For instance, there is no free ethylenediamine ligand available,
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although the SeMet monochelate is still being produced. This ag
again
ain would make sense

due to the SeMet favoring monochelate formation at higher pH
pH.. After 12 hours of
reaction the spectrum still looks the same with no free ethylenediamine being produced
and only the SeMet monochelate being produced as shown in the following figure:
Figure 3.23)

Free SeMet

[Pt(en)(SeMet-Se,N)]

1

H NMR Spectrum of [Pt(en)(ox)]2+ & excess SeMet at pH 7.0 after 5 days

Even after only a few days the pH had only drop
dropped
ped from 6.9 to 5.3, which again
insinuates that only the SeMet bischelate can be formed under these conditions at a low

pH of around 4.0, due to the SeMet becoming deprotonated at a high pH.

IV.

DISCUSSION

Confirmed metabolites of patients taking cisplatin include the methionine
monochelate, so potentially selenomethionine could be a potential metabolite of patients
since platinum kinetically prefers reactions with selenium rather than sulfur.12,11 After
injecting rats with cisplatin, Pt(II)-methionine complexes have been reportedly produced
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and relatively quickly, and potentially selenomethionine complexes would be produced
as well.12
This research was typically monitored via 1H NMR spectroscopy, and to confirm
our results we used LC/MS. Once the results from the Liu et al. paper could not be
replicated we determined to study selenomethionine, as products were much easier to
assign and we had previously studied reactions with selenomethionine and platinum.
Using Norman et al. method, we were able to reproduce the methionine
monochelate, and we used a similar strategy to form the selenomethionine monochelates
as well. Reacting potassium tetrachloroplatinate(II) and selenomethionine with sodium
chloride at a 1:1 ratio produces the selenomethionine monochelate. When reacting the
same reagents but at a 1:2 ratio, there are three different isomers of the bischelate formed;
RR, RS, and SS. In order to confirm our results we used LC/MS and obtained a mass of
585 which corresponded to the [Pt(SeMet-Se,N)2] 2+, and the monochelate produced a
mass of 460 (M-1) giving the product [Pt(SeMet-Se,N)Cl2] 2+. When comparing the
SeMet monochelate to that of Norman et al. Met monochelate, the ratio of isomers is
relatively similar.12 Also, when comparing the SeMet and Met bischelates, the most
stable isomer formed is the cis product with both Met and SeMet bischelates, while only
small traces of trans isomers were produced only in the Met bischelate.11,12 This is of
interest because a complex conveyed as the trans isomer of [Pt(Met-S,N)2] 2+ was
isolated in patients treated with cisplatin, but the cis isomer could be potentially
explained due to selenium having an increased π-accepting ability over sulfur.11,12
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When trying to react 6 mM [Pt(Met-S,N)Cl2] 2+ with 3 mM SeMet, various
products are formed. When both monochelates of Met and SeMet were formed with this
solution, this would suggest that there was free potassium tetrachloroplatinate available
for the SeMet to react with thus forming the monochelate. In this reaction there was
never any free methionine produced, which would also suggest that there is free platinum
for the SeMet to react with. Free platinum from K2PtCl4 would not show up in a proton
NMR, and having previously checked the [Pt(Met-S,N)Cl2] 2+ sample, there wasn’t any
free methionine, so it was assumed that everything was done reacting. However, the
results suggested otherwise by the formation of both monochelates.
After adding additional SeMet to the solution, similar peaks were produced when
compared to the reaction of 6 mM [Pt(Met-S,N)Cl2] 2+ and 6 mM SeMet. The equimolar
solution produced various peaks, producing two sets of three peaks and the pairs of peaks
were extremely similar to one another suggesting that some sort of species consisting of a
methionine, selenomethionine bonding to a platinum atom being produced. The peaks
from the 6 mM [Pt(Met-S,N)Cl2]2+ and 3 mM SeMet with the extra addition of SeMet
after a few days resulted in comparable peaks to that of the equimolar ratio solution
which would again suggest a species containing both methionine and selenomethionine
joining a platinum atom. Using LC/MS to help confirm our results after adding the
additional selenomethionine a mass of 574 was produced which is consistent with a
species consisting of both methionine and selenomethionine having been connected to
one platinum atom, because either SeMet or Met is chelated to platinum while the other is
only a monoadduct. With LC/MS one cannot determine specifically which is chelated
and which is not. However, we tried to compare alpha hydrogens of both a methionine
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monochelate and a selenomethionine monochelate, but the resolution from the NMR
spectrum is not good enough to come to a definitive conclusion on which is chelated and
not.
When both amino acids were mixed together in one vial, while the platinum and
sodium chloride were mixed in a separate vial and later both vials mixed together, it was
never thought that only monochelates would form. After looking at the NMR spectrum
and noticing only monochelates developing, it was observed that one isomer was formed
preferentially. The methionine monochelate in previous papers has already been
determined that isomer A (Figure 3.2) is favored due to the methyl group that is pointed
away from the rest of the structure creating less steric hindrance. When looking at the
monochelates formed by selenomethionine, it could be determined that one isomer is also
favored, and could be concluded that it is isomer B (Figure 3.2). This could also be
concluded due to the methyl group having less steric hindrance when pointed away from
the rest of the structure.
When reacting selenomethionine with [Pt(en)ox] 2+ various products are formed
and some products are not formed at a higher pH. When using excess SeMet at a pH of
4.0 the SeMet bischelate is formed through a [Pt(en)(SeMet-Se)2] 2+ intermediate and
then releases free ethylenediamine. This would mean that the second SeMet is competing
with the amine group from the first bonded SeMet, and would insinuate that the amine is
less protonated making the Se a better ligand rather than the amine ligand. A reaction
scheme below shows the formation of the SeMet bischelate:
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Reaction Scheme forming SeMet bischelate at pH 4.0

However, using the same conditions and only changing the pH up to 7.0, there is
no free ethylenediamine produced and no SeMet bischelate formed, only the SeMet
monochelate is produced. This would suggest again that at a higher pH the amine group
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on the first bonded SeMet is more deprotonated making it a better ligand this time rather
than a second Se of SeMet.
Figure 4.2)

pH 7

NH2

H2N

Pt

O

O

O

O

+ excess SeMet

NH2

H2N

Pt
Se

+

NH2

O
O
Reaction Scheme forming SeMet monochelate at pH 7.0

Also, when using excess platinum but at a low pH, a small amount of
ethylendiamine is available, but a SeMet monochelate is produced, and the SeMet
monoadduct is formed as well. The following reaction scheme depicts the products
formed at a pH 4.0 with excess platinum:
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Figure 4.3)
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Reaction Scheme forming SeMet monochelate at pH 4.0

Since the SeMet bischelate is formed at a low pH when using [Pt(en)ox]2+, this
can be explained due to the SeMet becoming deprotonated when adding another SeMet to
the platinum releasing a hydrogen in relatively acidic conditions and additionally
dropping the pH even further allowing chelation to occur. At a pH of 4.0 this occurs
relatively quickly, and doesn’t occur at all in pH of 7.0. When using excess of platinum
at a low pH the SeMet bischelate does not form and there is very little free
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ethylenediamine ligand available when compared to using excess SeMet at pH 4.0.
While many papers have reported a [Pt(dach)(Met-S,N)] 2+ product, a bischelate using
the ligand DACH has not been produced, and may could be due to the previous studies
being done at a pH of around 7.0, while it seems that the bischelate can be produced at a
lower pH instead of a higher pH.
V.

CONCLUSION

These metabolites are interesting as both selenomethionine and methionine are
found in the body and once a patient takes a platinum(II) anticancer medication, these
results could be similar to ones formed inside the body. The fact that a sulfur and
selenium containing amino acid can bind to potentially the same platinum forming
similar products at relatively similar rates is intriguing and what would happen with these
products in the body are interesting.
These results show that a methionine and selenomethionine can bind to the same
platinum molecule. The selenomethionine monochelate is also formed when reacting at a
1:1 ratio; the bischelate was not formed with any of these reactions when methionine and
selenomethionine are both present in solution.
There is still further work to be done with these results such as confirming which
amino acid is chelated versus which is not and which isomers are formed. Using these
results and trying similar experiments using selenocystine or cysteine would be another
plausible area to explore.
In concluding the results with the reactions of [Pt(en)ox] 2+ and SeMet a
bischelate is formed at a lower pH and is not formed at a higher pH. This would suggest
that at a higher pH the monochelate is only formed due to the amine nitrogen on the first
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coordinating SeMet adduct being more deprotonated and making a better ligand rather
than another SeMet being coordinated and then forming the bischelate. While at a lower
pH it is just the opposite and suggests a competition for the amine group of the first
coordinated SeMet adduct and the second SeMet-Se, making the Se of the second SeMet
a better ligand than the amine group of the first SeMet.
Many of these results are of interest due to the known metabolites that have been
produced in patients taking platinum(II) medications. In summary many new products
have been synthesized and formed at different pH’s which gives new insight into trying
various platinum compounds at lower pH’s to see if bischelates can be formed.
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